Helen Barraclough

Phase III, Open-Label, Randomized Study Comparing Concurrent Gemcitabine Plus Cisplatin and Radiation Followed by Adjuvant Gemcitabine and Cisplatin Versus Concurrent Cisplatin and Radiation in Patients With Stage IIB to IVA Carcinoma of the Cervix

Alfonso Dueñas‐González, Juan José Zarbá, Firuza D. Patel et al. · Journal of Clinical Oncology · 2011 · 468 citations · Full text

Biostatistics Primer: What a Clinician Ought to Know: Hazard Ratios

Helen Barraclough, Lorinda Simms, Ramaswamy Govindan · Journal of Thoracic Oncology · 2011 · 101 citations · Full text

Cancer Epidemiology, Clinical Endpoint, Prognosis +8

A Randomized Phase 3 Trial Comparing Pemetrexed/Carboplatin and Docetaxel/Carboplatin as First-Line Treatment for Advanced, Nonsquamous Non-small Cell Lung Cancer

José Rodrigues-Pereira, Joo-Hang Kim, Manuel Magallanes et al. · Journal of Thoracic Oncology · 2011 · 94 citations · Full text

Medicine, Trial Comparing Pemetrexed/carboplatin, Clinical Trials +9

Evolutionary Relationships and Protein Domain Architecture in an Expanded Calpain Superfamily in Kinetoplastid Parasites

Klaus Ersfeld, Helen Barraclough, Keith Gull · Journal of Molecular Evolution · 2005 · 88 citations

Biology, Protein Domain Architecture, Protein Function +8

Efficacy in high burden locally advanced cervical cancer with concurrent gemcitabine and cisplatin chemoradiotherapy plus adjuvant gemcitabine and cisplatin: Prognostic and predictive factors and the impact of disease stage on outcomes from a prospective randomized phase III trial

Alfonso Dueñas‐González, Mauro Orlando, Yexi Zhou et al. · Gynecologic Oncology · 2012 · 51 citations

Advanced Cervical Cancer, Cisplatin Chemoradiotherapy, Cervical Cancer Management +10